Cargando…

An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma

PURPOSE: We conducted this phase I/II clinical trial to determine the safety and efficacy of lower-dose decitabine based therapy in pretreated patients with advanced HCC. EXPERIMENTAL DESIGN: Patients with advanced HCC were eligible. The administered dose of decitabine was 6 mg/m(2)/d intravenously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Qian, Chen, Meixia, Lu, Xuechun, Li, Xiang, Duan, Feng, Wang, Maoqiang, Luo, Guangbin, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599300/ https://www.ncbi.nlm.nih.gov/pubmed/25895027

Ejemplares similares

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
por: Fan, Hui, et al.
Publicado: (2014)

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial
por: Dai, Hanren, et al.
Publicado: (2020)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
por: Liu, Hui, et al.
Publicado: (2023)

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
por: Wu, Depei, et al.
Publicado: (2015)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021)

DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire
por: Nie, Jing, et al.
Publicado: (2016)

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
por: Hua, Yijun, et al.
Publicado: (2021)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study
por: Ye, Li, et al.
Publicado: (2021)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study
por: Li, Xiaoyang, et al.
Publicado: (2019)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma
por: van der Westhuizen, Andre, et al.
Publicado: (2020)

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
por: Wirth, Lori J., et al.
Publicado: (2021)

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma
por: Lin, Shi-Ming, et al.
Publicado: (2016)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
por: Fiedler, Walter, et al.
Publicado: (2022)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial
por: Slopis, John M., et al.
Publicado: (2018)

Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients
por: Tomita, Yoshihiko, et al.
Publicado: (2020)

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
por: Chaft, Jamie E., et al.
Publicado: (2022)

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
por: Santini, V, et al.
Publicado: (2018)

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
por: Drake, M J, et al.
Publicado: (2003)

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
por: Inaki, Anri, et al.
Publicado: (2021)

Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)
por: Sun, Yongkun, et al.
Publicado: (2021)

Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study
por: Marty, Francisco M., et al.
Publicado: (2014)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
por: Ramalho, Dario Brock, et al.
Publicado: (2018)

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
por: Reville, Patrick K., et al.
Publicado: (2021)

Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
por: Zhu, Jun, et al.
Publicado: (2021)

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
por: Song, Zhengbo, et al.
Publicado: (2022)

Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reports
por: LIN, JIE, et al.
Publicado: (2013)

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
por: Jung, Ki Sun, et al.
Publicado: (2018)

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Lan, Chunyan, et al.
Publicado: (2020)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
por: Mao, Lili, et al.
Publicado: (2022)

Treatment of Breast Cancer-Related Lymphedema With Topical Tacrolimus: A Prospective, Open-Label, Single-Arm, Phase II Pilot Trial
por: Gulmark Hansen, Frederik C., et al.
Publicado: (2023)

Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)—Phase II single-arm open-label feasibility study
por: Lee, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lagb5u5lfqjcog2qvrbfgeka24